文献速递甲状腺疾病

摄碘率与甲状腺球蛋白引导的分化型甲状腺癌残留消融随机对照研究

Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
PubMed 文献 · Thyroid · 2019-01-01

该前瞻性随机开放标签对照试验纳入277例分化型甲状腺癌术后患者,按4:1随机分为摄碘率联合甲状腺球蛋白引导组(n=207)与固定3.7 GBq组(n=58)。引导组所用131I活度显著低于固定组,且成功残留消融率显著更高(94.2% vs 70.7%,P<0.0001),中期不良反应(主要为口干)发生率更低。

要点

  • 摄碘率联合Tg引导的残留消融可降低131I活度并提高消融成功率。
  • 引导组四个亚组间成功消融率相当(P=0.543)。
  • 引导组中期不良反应(以口干为主)发生率显著低于固定活度组。

核心结论

  • 与固定3.7 GBq相比,摄碘率联合甲状腺球蛋白引导的剂量学方法可提高分化型甲状腺癌术后残留消融成功率并降低中期不良反应发生率。

研究设计与样本

  • 前瞻性、随机、开放标签、对照试验,277例分化型甲状腺癌术后患者按4:1随机分为摄碘率联合甲状腺球蛋白引导组(n=207)与固定3.7 GBq组(n=58)。

主要发现

  • 引导组所用131I活度为3.26±1.54 GBq,显著低于固定活度组(P<0.0001)。
  • 引导组成功残留消融率为94.2%,显著高于固定活度组的70.7%(P<0.0001)。
  • 引导组四个亚组的成功残留消融率相当(P=0.543)。
  • 两组总不良反应/短期不良反应发生率无统计学显著差异,但引导组中期不良反应(以口干为主)发生率显著更低。

关键数值与推荐

  • 引导组依据摄碘率四级(≤2%、2-5%、5-15%、>15%)与Tg四级(≤2、2-5、5-10、>10 ng/mL)确定131I活度分别为1.1、1.85、3.7、5.55 GBq。
  • 若摄碘率与Tg水平不在同一类别,则按两者中较高类别对应的活度给药。
  • 成功残留消融定义为消融后6个月及以上在促甲状腺激素刺激下诊断性全身扫描阴性且Tg<1 ng/mL(抗Tg抗体阴性),或诊断性全身扫描阴性(抗Tg抗体阳性)。

临床怎么用

  • 对分化型甲状腺癌术后拟行残留消融者,可考虑以摄碘率联合甲状腺球蛋白引导个体化活度,而非一律使用固定3.7 GBq。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioiodine (131I) remnant ablation (RRA) has become a key step in the postoperative treatment of differentiated thyroid cancer (DTC). However, inadequate or excessive 131I is common using fixed activities. This study was designed to explore the feasibility of radioiodine uptake and thyroglobulin (RAIU-Tg)-guided RRA. METHODS: A total of 277 patients were randomized to the RAIU-Tg-based activity group or a fixed activity of 3.7 GBq group at a ratio of 4:1. The RAIU-Tg-based activity was established based on four levels of RAIU (≤2%, 2-5%, 5-15%, and >15%) and Tg levels (≤2, 2-5, 5-10, and >10 ng/mL). Based on this, 131I activities of 1.1, 1.85, 3.7, and 5.55 GBq were administered. If the levels for RAIU and Tg were not in the same category, the higher activity determined by either RAIU or Tg was administered. Successful RRA was defined as negative diagnostic whole-body scan and Tg <1 ng/mL (anti-Tg antibody negative) or negative diagnostic whole-body scan (anti-Tg antibody positive) under thyrotropin stimulation six months or more post RRA. RESULTS: There was no statistically significant difference in baseline characteristics between the RAIU-Tg-based activity group (n = 207) and the fixed activity group (n = 58). The activity of 131I used in the RAIU-Tg-based activity group (3.26 ± 1.54 GBq) was significantly lower than that used in the fixed activity group (p < 0.0001), whereas the rate of successful RRA in the RAIU-Tg-based activity group was significantly higher than the rate in the fixed activity group (94.2% vs. 70.7%; p < 0.0001). The rates of successful RRA in the four subgroups of the RAIU-Tg-based activity group were comparable (p = 0.543). Although there was no statistically significant difference in the incidence of total/short-term adverse effects between the RAIU-Tg-based activity group and the fixed activity group, a significantly lower incidence of intermediate adverse effects, which predominantly consisted of xerostomia, was reported in the RAIU-Tg-based activity group. CONCLUSIONS: Compared to a fixed activity of 3.7 GBq, RAIU-Tg-guided dosimetry can improve the success rate and decrease the incidence of intermediate side effects of RRA in postoperative patients with DTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Jin Y, Ruan M, Cheng L, et al. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial. Thyroid. 2019. PMID: 30560716. doi:10.1089/thy.2018.0028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。